



## (51) International Patent Classification:

*A61K 9/19* (2006.01) *A61K 47/26* (2006.01)  
*A61K 47/18* (2006.01) *A61K 38/47* (2006.01)  
*A61K 47/22* (2006.01) *A61K 47/68* (2017.01)  
*A61K 47/12* (2006.01) *A61P 3/00* (2006.01)  
*A61K 47/02* (2006.01) *A61P 43/00* (2006.01)

## (21) International Application Number:

PCT/KR2023/003300

## (22) International Filing Date:

10 March 2023 (10.03.2023)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

10-2022-0032091 15 March 2022 (15.03.2022) KR

(71) Applicants: **GREEN CROSS CORPORATION**

[KR/KR]; 107, Ihyeon-ro 30beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do 16924 (KR). **HANMI PHARM. CO., LTD.** [KR/KR]; 214, Muha-ro, Paltan-myeon, Hwaseong-si, Gyeonggi-do 18536 (KR).

(72) Inventors: **KIM, Miroo**; R&D Center, 93, Ihyeon-ro 30beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do 16924 (KR). **YOO, Miri**; R&D Center, 93, Ihyeon-ro 30beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do 16924 (KR). **SON, Jae Woon**; R&D Center, 93, Ihyeon-ro 30beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do 16924 (KR). **PARK, Da-eui**; R&D Center, 93, Ihyeon-ro 30beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do 16924 (KR). **YI, Shin-Ae**; R&D

Center, 93, Ihyeon-ro 30beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do 16924 (KR). **KIM, Jin Young**; 550, Dongtangiheung-ro, Hwaseong-si, Gyeonggi-do 18469 (KR). **PARK, Jun Sub**; 550, Dongtangiheung-ro, Hwaseong-si, Gyeonggi-do 18469 (KR). **JANG, Doo Seo**; 550, Dongtangiheung-ro, Hwaseong-si, Gyeonggi-do 18469 (KR). **HONG, Sung Hee**; 550, Dongtangiheung-ro, Hwaseong-si, Gyeonggi-do 18469 (KR). **KIM, Sang Yun**; 550, Dongtangiheung-ro, Hwaseong-si, Gyeonggi-do 18469 (KR).


(74) Agent: **HANOL INTELLECTUAL PROPERTY & LAW**; 6F, 135, Beobwon-ro, Songpagu, Seoul 05836 (KR).

## (81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

## (84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: LYOPHILIZED FORMULATION COMPRISING A FUSION PROTEIN INCLUDING  $\alpha$ -GALACTOSIDASE A

(57) Abstract: The present invention relates to a lyophilized formulation including a fusion protein of  $\alpha$ -galactosidase A and a preparation method thereof, wherein the lyophilized formulation not only has storage stability by including a composition providing structural stability to a fusion protein of  $\alpha$ -galactosidase A, but also has excellent stability although the fusion protein is contained at a high concentration.

[Continued on next page]

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*